Medicus Pharma's Non-Invasive Treatment Clears 73 Percent of Skin Lesions in Latest Trial

Toronto, Wednesday, 18 March 2026.
Medicus Pharma’s SkinJect therapy cleared 73 percent of lesions in a recent trial. This breakthrough suggests nearly three-quarters of patients might soon bypass immediate, invasive surgical interventions.